Biomarker panel for chronic graft-versus-host disease

Journal of Clinical Oncology

Volumn 34, Issue 22, 2016, Pages 2583-2590

  Yu, Jeffrey ^a   Storer, Barry E ^b,c   Kushekhar, Kushi ^a   Zaid, Mohammad Abu ^a   Zhang, Qing ^b   Gafken, Philip R ^b   Ogata, Yuko ^b   Martin, Paul J ^b   Flowers, Mary E ^b   Hansen, John A ^b   Arora, Mukta ^d   Cutler, Corey ^e   Jagasia, Madan ^f   Pidala, Joseph ^g   Hamilton, Betty K ^h   Chen, George L ⁱ   Pusic, Iskra ^j   Lee, Stephanie J ^b   Paczesny, Sophie ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CD146 ANTIGEN; CORTICOSTEROID; CXCL9 CHEMOKINE; OSTEOPONTIN; SELP PROTEIN; STEM CELL FACTOR; STROMELYSIN; SUPPRESSION OF TUMORIGENICITY 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MORBIDITY; MORTALITY; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; TIME FACTOR;

ADULT; BIOMARKERS; CHEMOKINE CXCL9; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOPONTIN; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84979207845     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.9615     Document Type: Article

References (31)

1. Flowers ME, Parker PM, Johnston LJ, et al: Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Longterm follow-up of a randomized trial. Blood 100: 415-419, 2002
2. Zecca M, Prete A, Rondelli R, et al: Chronic graft-versus-host disease in children: Incidence, risk factors, and impact on outcome. Blood 100: 1192-1200, 2002
3. Anasetti C, Logan BR, Lee SJ, et al: Peripheralblood stem cells versus bone marrow from unrelated donors. N Engl J Med 367:1487-1496, 2012
4. Socié G, Stone JV, Wingard JR, et al: Longterm survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 341:14-21, 1999
5. Lee SJ, Klein JP, Barrett AJ, et al: Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 100: 406-414, 2002
6. Jagasia MH, Savani BN, Stricklin G, et al: Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 15:1288-1295, 2009
7. Lee SJ, Wolff D, Kitko C, et al: Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 21:984-999, 2015
8. Pavletic SZ, Vogelsang GB, Lee SJ: 2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: Preface to the series. Biol Blood Marrow Transplant 21:387-388, 2015
9. Paczesny S, Hakim FT, Pidala J, et al: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group report. Biol Blood Marrow Transplant 21:780-792, 2015
10. Martin PJ, Lee SJ, Przepiorka D, et al: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group report. Biol Blood Marrow Transplant 21:1343-1359, 2015
11. Paczesny S, Krijanovski OI, Braun TM, et al: A biomarker panel for acute graft-versus-host disease. Blood 113:273-278, 2009
12. Paczesny S, Braun TM, Levine JE, et al: Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2:13ra2, 2010
13. Ferrara JL, Harris AC, Greenson JK, et al: Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118:6702-6708, 2011
14. Vander Lugt MT, Braun TM, Hanash S, et al: ST2 as a marker for risk of therapy-resistant graft versus- host disease and death. N Engl J Med 369: 529-539, 2013
15. Pidala J, Sarwal M, Roedder S, et al: Biologic markers of chronic GVHD. Bone Marrow Transplant 49:324-331, 2014
16. Chronic GVHD Consortium: Rationale and design of the chronic GVHD cohort study: Improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant 17:1114-1120, 2011
17. Arora M, Cutler CS, Jagasia MH, et al: Incidence, risk factors, and prognosis of late immunemediated disorders after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 21: S54, 2015
18. Kitko CL, Levine JE, Storer BE, et al: Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood 123:786-793, 2014
19. Sarantopoulos S, Stevenson KE, Kim HT, et al: High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 13:6107-6114, 2007
20. Levine JE, Paczesny S, Mineishi S, et al: Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111: 2470-2475, 2008
21. Croudace JE, Inman CF, Abbotts BE, et al: Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood 120:4246-4255, 2012
22. Hakim F, Memon S: Elevated expression of interferon-induced genes and damage associated molecular pattern receptor genes in chronic graft versus host disease. Biol Blood Marrow Transplant 20:S226, 2014
23. Liu W, Ren HY, Dong YJ, et al: Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis. Int J Hematol 96: 764-772, 2012
24. Koreth J, Stevenson KE, Kim HT, et al: Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 114: 3956-3959, 2009
25. Koreth J, Stevenson KE, Kim HT, et al: Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 30:3202-3208, 2012
26. Zhang J, Ramadan AM, Griesenauer B, et al: ST2 blockade reduces sST2-producing T cells while maintaining protectivem ST2-expressing T cells during graft-versus-host disease. Sci Transl Med 7:308ra160, 2015
27. Reichenbach DK, Schwarze V, Matta BM, et al: The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood 125:3183-3192, 2015
28. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221-233, 2007
29. Radisky DC, Levy DD, Littlepage LE, et al: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127, 2005
30. Vandenbroucke RE, Libert C: Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 13:904-927, 2014
31. Ross PL, Huang YN, Marchese JN, et al: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154-1169, 2004